Enovid Product FAQ

Enovid is a Nitric Oxide Release Spray (NORS), which protects users from viruses that enter the body through the upper nasal pathways. Each bottle contains enough supply for 1 month.

Click here for the Enovid User Guide.

Enovid is designed to kill SARs-CoV-2, the virus that causes COVID-19, in the upper airways, preventing it from incubating and spreading to the lungs.

Enovid contains a broad-spectrum antiviral that kills viruses and virus variants

Shown to be effective in the lab against a wide range of viruses

New variants of the coronavirus won’t interfere with its effectiveness

Each bottle contains a month’s supply for one person to spray twice a day for protection against viruses

Sodium chloride, citric acid, HPMC, sodium nitrite, Benzalkonium Chloride

Why isn’t Nitric Oxide listed as one of the ingredients?  A small amount of Nitric oxide is being created once the spray is being used. This is a patented technology that is creating nitric oxide.

Enovid is like a “hand sanitizer equivalent for the nose,” and creates a physical barrier in the nasal passages to stop viruses along with a “chemical barrier” of nitric oxide, which is known for its antimicrobial qualities.

Enovid shields against viruses and should be administered before and after suspected exposure to viruses by individuals in high-risk environments (i.e. public transportation, health care settings, daycares, shopping centers, sports events, etc)

Enovid may be applied 2-3 times over the day or up to 5 times a day following suspected exposure to viruses.

Discard the Enovid sprayer on the expiration date printed on the sprayer or 60 days after the first opening, whichever comes first.

Enovid is the brand name of the Nitric Oxide Nasal Spray (NONS) developed and manufactured by SaNOtize Research and Development Corp. based in Vancouver, BC, and marketed by Reekooz for our customers in the US

Please consult the User Guide insert in the box.

It is recommended that if you experience reactions such as headache, nosebleed, or a persistent nasal burning sensation (that is, continues for > 5 minutes after each administration or is not tolerated), to discontinue using the product immediately. If symptoms persist, consult your Healthcare Provider.

Although clinical trial safety data and commercial pharmacovigilance monitoring data indicate a high benefit-to-risk (safe) product profile, the manufacturers (Sanotize) have not yet conducted a long-term safety analysis. Plans are in process to address a long-term safety assessment associated with the product’s chronic use.